Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

27.46 +1.34 (+5.13%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
99 100 Next >
US Stocks Set To Open Weaker As Traders Eye Key Main Street Events: Analyst Sees Buying Opportunity On 'Stunning' Earnings Expectations
Several market-moving catalysts, including the release of the Fed minutes, a Federal Reserve speech, and JOLTS data, could influence the day's market movement. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Apple, Longboard Pharmaceuticals, Coinbase, Moderna, Tesla: Why These 5 Stocks Are On Investors' Radars Today
U.S. stocks experienced mixed results in Tuesday’s trading session. The Dow Jones index showed resilience, gaining around 25 points, a modest rise of 0.07% to 37,715.04. In contrast, the tech-heavy... 
Via Benzinga
Topics Stocks
Exposures US Equities
2023's Biggest Losers In The Russell 1,000
In this article, we show 35 Russell 1,000 members that fell by at least 30% during the year 2023. 
Via Talk Markets
2 Major Reasons Why Moderna (MRNA) Stock Is Up Today
One of the most beaten-down stocks of 2023 in the biotech space, Moderna is seeing a rebound today, with MRNA stock up 15%. 
Via InvestorPlace
Moderna Inc. (NASDAQ: MRNA) Highlighted for Surprising Price Action
Via Investor Brand Network
This Is What Whales Are Betting On Moderna
Via Benzinga
Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Longboard Pharmaceuticals, Inc. 
Via Benzinga
Tech Drags On Wall Street As 2024 Kicks Off; Dollar and Treasury Yields Surge: What's Driving Markets Tuesday?
Wall Street kicked off 2024 on a weaker note, with the S&P 500 dipping by 0.5%, and the Nasdaq 100 experiencing a 1.4% decline in midday trading in New York. 
Via Benzinga
What's Going On With Pfizer Stock?
Pfizer, Inc. (NYSE: PFE) shares are trading higher on the first trading day of 2024 after the stock lost more than 40% in 2023. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Tech Stalls As Rising Bond Yields Spook Investors
It's been an inauspicious start to the 2024 trading year, with all three major indexes in the red midday. 
Via Talk Markets
Moderna Analyst Projects Transformation Into 'Five-Product Commercial Company' By 2026
Moderna Inc (NASDAQ: MRNA) is back in focus as it is making advancements in cancer treatment. 
Via Benzinga
Moderna Stock Is Moving Higher: What's Going On?
Moderna Inc (NASDAQ: MRNA) shares are trading higher Tuesday following positive analyst coverage from Oppenheimer. 
Via Benzinga
2023 Will Go Down As The Year Pharma Showed Its Determination To Beat Cancer
During the last week of 2023, AstraZeneca PLC (NASDAQ: AZN) agreed to acquire Chinese cancer therapy developer Gracell Biotechnologies Inc. 
Via Benzinga
Moderna Stock Is Climbing Thanks to Merck, But Is It Still a Buy?
The pair's collaboration is making waves, and there's more to come. 
Via The Motley Fool
Pharmaceutical Giants Brace for Showdown as Medicare Drug Price Negotiations Are Poised For 2024
2024 will mark a pivotal moment for the healthcare industry, particularly in drug pricing negotiations. 
Via Benzinga
Thoughts For Thursday: With War Clouds As A Backdrop The Market Is Set To End The Year On A High
The market looks set to end 2023 on a high note, but 2024 is less certain, particularly because though, the US does not want further action in the Gulf, it seems, Iran via its proxies is gaming for... 
Via Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
The Winners and Losers: 2023 Stock Market Performance Review
The 2023 stock market saw steep declines followed by rapid upswings, but we're ending the year on a high note (even if some stocks aren't). 
Via InvestorPlace
Why Is RayzeBio (RYZB) Stock Up 100% Today?
RYZB stock has doubled today after Bristol Myers Squibb shelled out $4.1 billion to buy RayzeBio. Expect more such deals in 2024. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Should You Buy This Year's Worst-Performing S&P 500 Stocks for 2024?
Some of this year's underperformers could have brighter futures. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
HBM Gets Health Boost From Drug Licensing Deals
Key Takeaways: Nona Biosciences, a subsidiary of HBM Holdings, has struck a licensing-out deal with a Pfizer-owned biotech  for an initial sum of $53 million and milestone payments of up to $1.05... 
Via Benzinga
S&P 500, Nasdaq 100 Aim For 8th Week Of Gains As Fed's Inflation Gauge Cools: What's Driving Markets Friday?
The S&P 500 and Nasdaq 100 indices are on the verge of achieving an impressive eight consecutive weeks of gains following a more significant decline than expected in the Federal Reserve’s favored... 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Pfizer's chaotic year wraps up with plunging stock, grim guidance
Pfizer's tumultuous 2023 included a 41.84% stock plunge as revenue from Covid drugs fell. Disappointing 2024 guidance resulted in analysts slashing targets. 
Via MarketBeat
Exposures COVID-19
Moderna to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Via ACCESSWIRE
COVAX Global Initiative For COVID-19 Vaccines Comes To An End Amid Shift To Regular Programs
COVAX, the multilateral mechanism for equitable global access to COVID-19 vaccines launched in 2020, will close on 31 December 2023.&n 
Via Benzinga
Exposures COVID-19
Long-Term, Organic Revenue Growth Is A Key To Investment Success
Revenue growth is probably the easiest of the 4 check boxes to quantify. Anyone can pull up their broker's research pages, or Yahoo Finance, and look at the past 3 or 5 years of revenue. 
Via Talk Markets
Is It Time to Buy the S&P 500's 4 Worst-Performing Stocks This Year?
One retail chain may have the clearest path to market-beating upside from here. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
QQQ And QQQM ETFs Top Gainers And Laggards Of 2023
This article will look at the top gainers and laggards of the two popular ETFs, which have over $17 billion and $223 billion assets, respectively. The two funds are similar, with the only difference... 
Via Talk Markets
Topics ETFs
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.